[{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IBD0333","moa":"4-1BB \/ CD24","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"BMND08","moa":"5-HT2A receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","highestDevelopmentStatusID":"7","companyTruncated":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo"},{"orgOrder":0,"company":"Clinical Testing of Beverly Hills","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Clinical Testing of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinical Testing of Beverly Hills \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Clinical Testing of Beverly Hills \/ Galderma"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MV130","moa":"Bacterial antigens","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HYP-2090PTSA","moa":"Class 1 PI3K\/KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TURKEY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Diclofenac Potassium","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Orinove","sponsor":"Fosun Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ORIN1001","moa":"Endoplasmic reticulum to nucleus signaling 1 (ERN1)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Orinove","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orinove \/ Fosun Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Orinove \/ Fosun Pharma"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lazertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Globe Biotech Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BANGLADESH","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Erythropoietin Alfa","moa":"EPO receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Globe Biotech Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Globe Biotech Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Globe Biotech Limited \/ Undisclosed"},{"orgOrder":0,"company":"PureTech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LYT-300","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"PureTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"PureTech \/ Novotech"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hepenofovir Fumarate","moa":"HBV DNA polymerase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"McGill University","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Lallemand Health Solutions","highestDevelopmentStatusID":"7","companyTruncated":"McGill University \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"D3S-001","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Undisclosed"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"D3S-001","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"D3 Bio \/ Fortrea","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Fortrea"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV8.hLCA5","moa":"LCA5","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ University of Pennsylvania"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zampilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Zampilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Frontier Biotechnologies | Shanghai Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FB2001","moa":"Mpro","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ruijin Hospital \/ Frontier Biotechnologies | Shanghai Center for Disease Control and Prevention","highestDevelopmentStatusID":"7","companyTruncated":"Ruijin Hospital \/ Frontier Biotechnologies | Shanghai Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Vanda Pharmaceuticals \/ Mayo Clinic"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ADX-629","moa":"RASP","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"MAXVAX Biotechnology","sponsor":"Henan Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Respiratory Syncytial Virus Vaccine","moa":"RSV","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"MAXVAX Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAXVAX Biotechnology \/ Henan Center for Disease Control and Prevention","highestDevelopmentStatusID":"7","companyTruncated":"MAXVAX Biotechnology \/ Henan Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine","moa":"RSV","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"EYEGENE","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EG-COVID-003","moa":"SARS-CoV-2 spike protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"EYEGENE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"EYEGENE \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"EYEGENE \/ Novotech"},{"orgOrder":0,"company":"Empower Research","sponsor":"Empower Psychedelics | Centre for Neurology Studies | Mitacs","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Empower Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Empower Research \/ Empower Psychedelics | Centre for Neurology Studies | Mitacs","highestDevelopmentStatusID":"7","companyTruncated":"Empower Research \/ Empower Psychedelics | Centre for Neurology Studies | Mitacs"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glumetinib","moa":"tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Glumetinib","moa":"tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Glumetinib","moa":"tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Immunophage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IPG7236","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Nanjing Immunophage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Immunophage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanjing Immunophage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Undisclosed"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CHI-560","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Canopy Growth Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Prothya Biosolutions","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Cofact","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Prothya Biosolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothya Biosolutions \/ PRA Health Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Prothya Biosolutions \/ PRA Health Sciences"},{"orgOrder":0,"company":"ExeGi","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ The Emmes Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ION440","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Juntendo University","sponsor":"Junten Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"JB-101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Juntendo University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juntendo University \/ Junten Bio","highestDevelopmentStatusID":"7","companyTruncated":"Juntendo University \/ Junten Bio"},{"orgOrder":0,"company":"Xenothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LIS1","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Xenothera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenothera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xenothera \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chenland Nutritionals","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Moodelite T-4003-1","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Chenland Nutritionals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chenland Nutritionals \/ KGK Science","highestDevelopmentStatusID":"7","companyTruncated":"Chenland Nutritionals \/ KGK Science"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Shanghai AbelZeta Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MPCs-derived exosomes","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ruijin Hospital \/ Shanghai AbelZeta Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Ruijin Hospital \/ Shanghai AbelZeta Ltd."},{"orgOrder":0,"company":"Songqi Gao","sponsor":"Gabrail Cancer Center Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MT218","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Songqi Gao","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Songqi Gao \/ Gabrail Cancer Center Research","highestDevelopmentStatusID":"7","companyTruncated":"Songqi Gao \/ Gabrail Cancer Center Research"},{"orgOrder":0,"company":"Rion","sponsor":"Henry M. Jackson Foundation | Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Pep Purified Exosome Product","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ Henry M. Jackson Foundation | Walter Reed National Military Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Rion \/ Henry M. Jackson Foundation | Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pneumococcal 26-valent Conjugate Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RNK08954-01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ranok Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Meribank Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Meribank Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meribank Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Meribank Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Intralytix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Vrelysin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Intralytix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Intralytix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intralytix \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Puhe Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"YK-029A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Suzhou Puhe Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Puhe Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Puhe Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HY07121","moa":"Unknown","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Altesa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Changchun BCHT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Changchun BCHT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changchun BCHT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Changchun BCHT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vanarix SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vanarix SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vanarix SA \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vanarix SA \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Best Buy Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brigham and Women's Hospital \/ Best Buy Health","highestDevelopmentStatusID":"7","companyTruncated":"Brigham and Women's Hospital \/ Best Buy Health"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Respiratory Syncytial Virus Vaccine

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Respiratory Syncytial Virus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 07, 2022

                          Lead Product(s) : Respiratory Syncytial Virus Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Vanarix SA

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Vanarix SA

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 26, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 19, 2025

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Lead Product(s) : BMND08

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : BMND08 is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : BMND08

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Lead Product(s) : Pep Purified Exosome Product

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Henry M. Jackson Foundation | Walter Reed National Military Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Pep Purified Exosome Product is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : Pep Purified Exosome Product

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Henry M. Jackson Foundation | Walter Reed National Military Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : CM313 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          January 24, 2025

                          Lead Product(s) : CM313

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Beijing Zhifei Lvzhu Biopharmaceutical

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Beijing Zhifei Lvzhu Biopharmaceutical

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Details : Pneumococcal 26-valent Conjugate Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 25, 2024

                          Lead Product(s) : Pneumococcal 26-valent Conjugate Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : ASC30 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 08, 2024

                          Lead Product(s) : ASC30

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : RNK08954-01 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 31, 2024

                          Lead Product(s) : RNK08954-01

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          MAXVAX Biotechnology

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          MAXVAX Biotechnology

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Lead Product(s) : Recombinant Respiratory Syncytial Virus Vaccine

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Henan Center for Disease Control and Prevention

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Recombinant Respiratory Syncytial Virus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Recombinant Respiratory Syncytial Virus Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Henan Center for Disease Control and Prevention

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank